PR Newswire·Apr 28, 2026, 8:02 AM ET

Azitra, Inc. Announces Poster Presentation at ASGCT 2026 Highlighting ATR-01 Program for Ichthyosis Vulgaris

Azitra, Inc. presented new preclinical data for its ATR-01 program at the 2026 ASGCT Annual Meeting to support advancement toward first-in-human studies.
The candidate ATR01-616 is an engineered live biotherapeutic using a modified Staphylococcus epidermidis strain to deliver recombinant human filaggrin for treating ichthyosis vulgaris.
Peak secretion of recombinant human filaggrin occurred 6–8 hours following application in the demonstrated mechanism of action.
Ex vivo pig skin models showed significant reduction in transepidermal water loss across all dose levels with levels returning near baseline within 20 hours.
Studies in reconstructed human epidermis confirmed restoration of structural features, including increased filaggrin levels & co-localization with keratin proteins.
ATR01-616 utilizes an auxotrophic S. epidermidis strain designed for controlled growth & localized, sustained delivery of therapeutic filaggrin fragments.
The data builds on previous positive preclinical results to support progression into IND-enabling studies & a first-in-human clinical trial.
Azitra is also advancing ATR-12 for Netherton syndrome in a Phase 1b trial & ATR-04 for EGFR inhibitor-associated rash, which holds FDA Fast Track designation.
The company leverages a proprietary platform of approximately 1,500 engineered bacterial strains augmented by artificial intelligence & machine learning technologies.